Revolution Medicines, Inc. (RVMD) Shareholders & Insider Trades
Revolution Medicines shareholders at a glance
The largest holder of Revolution Medicines stock is Farallon Capital Management LLC, with 13.6 million shares (6.32% of the company), worth about $2.79 billion as of September 25, 2026. The 10 largest holders together own 47.4%.
In Q2 2026, 739 institutional holdings reports listed shares worth $40.40 billion.
Insiders reported 50 transactions in the last two years: 28 sales worth $12.71 million and no purchases. The newest one on file is from October 17, 2025 (Cislini Jeffrey Todd, General Counsel).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through October 17, 2025.
Revolution Medicines, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Revolution Medicines shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Farallon Capital Management LLC | 13.6 million | 6.32% | $2.8B |
| Fidelity Management & Research Co. LLC | 12.2 million | 5.69% | $2.5B |
| BlackRock Advisors LLC | 11.8 million | 5.49% | $2.4B |
| Baker Bros. Advisors LP | 11.4 million | 5.34% | $2.4B |
| Janus Henderson Investors US LLC | 10.7 million | 5.01% | $2.2B |
| Darwin Global Management Ltd. | 10.6 million | 4.96% | $2.2B |
| Vanguard Capital Management LLC | 9.1 million | 4.24% | $1.9B |
| Vanguard Portfolio Management LLC | 8.3 million | 3.87% | $1.7B |
| Nextech Invest AG | 7.6 million | 3.55% | $1.6B |
| Paradigm BioCapital Advisors LP | 6.4 million | 2.97% | $1.3B |
As of September 25, 2026.
Revolution Medicines institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 739 | – | $40.4B |
| Q1 2026 | 562 | 199.0 million | $19.1B |
| Q4 2025 | 410 | 201.0 million | $16.0B |
| Q3 2025 | 344 | 194.0 million | $9.1B |
| Q2 2025 | 329 | 191.0 million | $7.0B |
| Q1 2025 | 299 | 193.0 million | $6.8B |
| Q4 2024 | 301 | 193.0 million | $8.4B |
| Q3 2024 | 269 | 175.0 million | $7.9B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Revolution Medicines insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Cislini Jeffrey Todd | Oct 17, 2025 | General Counsel | Sale at price 55.00 per share. | $660,000 |
| Goldsmith Mark A | Oct 17, 2025 | Chief Executive Officer | Sale at price 50.47 - 55.00 per share. | $1.1M |
| Goldsmith Mark A | Oct 17, 2025 | Chief Executive Officer | Conversion of Exercise of derivative security at price 1.12 per share. | $22,400 |
| Cislini Jeffrey Todd | Oct 17, 2025 | General Counsel | Conversion of Exercise of derivative security at price 36.57 per share. | $438,840 |
| Kelsey Stephen Michael | Oct 13, 2025 | Officer | Sale at price 48.54 per share. | $1.2M |
| Kelsey Stephen Michael | Oct 13, 2025 | Officer | Conversion of Exercise of derivative security at price 4.73 per share. | $118,250 |
| Cislini Jeffrey Todd | Sep 24, 2025 | General Counsel | Sale at price 44.26 per share. | $79,624 |
| Anders Jack Lee | Sep 16, 2025 | Chief Financial Officer | Sale at price 45.82 per share. | $106,314 |
| Cislini Jeffrey Todd | Sep 16, 2025 | General Counsel | Sale at price 45.82 per share. | $85,647 |
| Horn Margaret A | Sep 16, 2025 | Chief Operating Officer | Sale at price 45.82 per share. | $218,814 |
| Lin Wei | Sep 16, 2025 | Officer | Sale at price 45.82 per share. | $98,982 |
| Kelsey Stephen Michael | Sep 16, 2025 | Officer | Sale at price 45.82 per share. | $245,942 |
Newest 12 of 50 insider transactions in the last two years.
Questions and answers
Who owns the most Revolution Medicines stock?
Farallon Capital Management LLC, with 6.32% of the company (as of September 25, 2026). Next: Fidelity Management & Research Co. LLC (5.69%) and BlackRock Advisors LLC (5.49%).
How many institutions own Revolution Medicines stock?
739 institutional holdings reports listed Revolution Medicines shares in Q2 2026 worth $40.40 billion.
Are Revolution Medicines insiders buying or selling the stock?
In the last two years insiders reported 28 sales and no purchases (50 transactions in all); the newest on file is from October 17, 2025.
